Merck KGaA, not Pfizer, lands consumer health deal with P&G worth $4.2B

Merck kgaa
Merck KGaA will hand P&G a consumer business that has grown 6% over the past two years. (Merck KGaA)

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Thursday, P&G said the two companies had inked a pact that will send Merck’s portfolio from Germany to Cincinnati, Ohio, for €3.4 billion ($4.21 billion). The pair expects to close the deal during the 2018-2019 fiscal year, it said.

RELATED: Merck KGaA mulls sale of undersized consumer health unit

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

The selloff agreement wraps up a sale process the Darmstadt-based drugmaker embarked on last September, pointing to “increasing internal constraints to fund” its consumer health business. And it’s “a clear demonstration of our continued commitment to actively shape our portfolio as a leading science and technology company,” CEO Stefan Oschmann said in a Thursday statement, adding, “With P&G we have found a strong, highly recognized player who has the necessary scale to successfully drive the business going forward.”

P&G, meanwhile, will pick up a $1 billion-by-sales business that’s grown 6% over the past two years and includes more than 900 products across 44 countries. And it’ll also fill a void left by a healthcare joint venture between P&G and Teva, which is set to end July 1.

RELATED: Undeterred by Pfizer's looming OTC sale, Merck KGaA scouts consumer health bidders

In selling off its OTC stable, Merck is succeeding where pharma giant Pfizer hasn't so far. With a price tag of some $20 billion in mind for its much larger unit, the New York drugmaker all but struck out after lead bidders Reckitt Benckiser and GlaxoSmithKline bailed. Earlier this month, though, rumors lingered that P&G could still be in the game as Pfizer’s last remaining suitor.

And on the Merck side, recent buzz centered on Mylan after players such as Reckitt Benckiser and Nestlé pulled back, though the generics behemoth last week vehemently denied it was interested.

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.